34
NT, non-treated; iso, isotype control antibody; 10k, ultracentrifugation fraction at 10k x 35 g; 100k, ultracentrifugation fraction at 100k x g; WT, wild-type; kDa, kilodalton; doxo, 
107
(H) Lists of proteins detected by mass spectrometry clustering into melanosome-like (WT)
108
EVs and exosome-like (BAG6KO) EVs and comparison to their respective cellular 109 levels. WT, wild-typeM; kDa, kilodalton; NT, non-treated; n.d., not detected.
111 112
Other supplement files related to Figure 2: 113 Table S1 . Transcriptomics of WT-and BAG6KO-EVs 
114

160
Representative microscopic images of macrophages after 7 days are shown.
161
EVs, extracellular vesicles; WT, wild-type; SSC, side scatter; OE, overexpression.
163
Other supplement files related to Figure 3: 164 
173
WT cell lysate was loaded as a control for antibody staining of the membrane. 
178
(C) Analysis of the EV release by NTA from WT or p53 siRNA knock down (kd) HEK293
179
cells that were either non-treated or treated with 100 nM doxorubicin or LBH for 16h.
180
Immunoblot for p53 and actin as a loading control is shown. 
193
(+WT BAG6) or with a N-terminal deleted BAG6 mutant (+nucBAG6), detected by 194 using a myc-tag specific antibody. Probing for GAPDH was done as a loading control.
195
The blot represents one out of three independent experiments. 
196
229
(A) Test of qRT-PCR assay robustness using cDNA made from RNA isolated out of 230 melanoma patient plasma EVs. The graph depicts a dilution series of EV cDNA using
231
RNA isolated from three plasma samples (mean ± SEM) and experiments in Figure   232 7B were performed at equal concentrations, either undiluted or diluted 1:2.
233
(B) Schematic representation of the BAG6R786* mutant protein.
234
(C) Immunoblot analysis of BAG6R786* mutant protein transfected into WT or BAG6KO
235
HEK293 cells using a BAG6 N-terminus-specific antibody which also detects the Murine splenocytes from Eµ:Tcl1a;Cd19:Cre mice were purified and cultured as described [8] .
328
The minimum purity of CD5+CD19+ B cells from mice was 85%. 
366
In vitro expression assay
367
In vitro expression experiments were performed using cell-free protein expression kit based 
371
Immunoprecipitation
372
Cell lysates or in vitro expressed proteins were precipitated using specific antibodies against 373 BAG6, p53, CBP/p300, HRS, ubiquitin or acetyl-lysine. A minimum of 1 µg of antibody were 374 used for 100 µg of total protein and Protein A magnetic beads were used for pull-down. 
399
Microscopy images were analysed with Leica Application Suite X 3.1.5.16308 and Imaris 8.3.1 400 software (3D reconstruction and cropping).
402
ELISA
403
The mouse monoclonal 3E4 (raised against the BAG6 N-terminus) and the BAG6-specific 404 chicken polyclonal 13pp2 antibodies (own lab) were used to detect BAG6 in a sandwich ELISA 405 procedure as previously described(10).
407
EV preparation
408
EVs were collected in cell culture for either 24 or 48h in either EV-depleted medium (overnight Table S5 .
452
Western Blot
453
Cells or EVs were lysed in buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.5% Triton X-100, 454 0.5% protease inhibitors). Cytoplasmic extraction of lysates was performed using soft lysis 455 conditions for 15 minutes with Triton X-100 lysis buffer followed by sequential centrifugation.
456
Protein concentration was measured with a BCA protein assay. 10 to 30 µg were loaded onto 457 sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels for blotting using standard 458 methods. Blots were incubated with primary antibody BAG6, p53, ALIX, CD81, HRS, flotillin-459 1, and p300 and TSG101.
460
The western blots were developed using X-ray films or by detection with a CCD camera. For 
488
Three independent experiments were performed.
490
Mass Spectrometry 
496
RT. Proteins were Lys-C digested for 2h at RT and afterwards solution was diluted to 1M urea 497 using 50 mM ABC buffer for trypsin digestion overnight at RT (both digests at 1 to 100 enzyme 498 to protein ratio). The reaction was stopped by acidification using 5% concentrated nitric 499 acid/0.2% trifluoroacetic acid before peptides were desalted on a C18 Stage tip.
500
All samples were analyzed at the CECAD proteomics facility (Cologne, Germany) on a Q-
501
Exactive Plus (Thermo Scientific) mass spectrometer that was coupled to an EASY nLC 1000
502
UPLC (Thermo Scientific). Briefly, peptides were loaded with solvent A (0.1% formic acid in 
508
Mass spectrometry bioinformatics and statistical analysis
509
All mass spectrometric raw data were processed with Maxquant using default parameters. 
